NeuroKey™ Grant Program:
Advancing Neurodegenerative Disease Research Together
About the Program
The NeuroKey™ Grant Program offers academic researchers and pharmaceutical/biotech companies the opportunity to analyze up to 75 human plasma samples at no cost using our NeuroKey™ assay. This multiplexed IP-MS assay targets key biomarkers relevant to neurodegenerative diseases, enabling researchers to generate high-quality data that will contribute to the scientific community’s understanding of these complex conditions.
Application Deadline: December 20, 2024
Sample Submission Deadline: March 7, 2025
Sample Types: Up to 75 plasma samples, with a minimum of 2 groups and 10 samples per group
Sample Requirements: Minimum 0.5 ml per sample (300 µl minimum, 500 µl recommended). At least 50 patients, divided into at least 2 groups (n=6 minimum, n=15 recommended)
Grant Award: NeuroKey™ analysis of up to 75 plasma samples
Eligibility: Open to scientists at all levels, including PhD students and post-doctoral researchers, working in academic institutions and pharma companies globally.
Program Duration: Selected applicants will be notified on a rolling basis, with public announcement of the grant winners.
Applicants must submit their proposal through the online application form by December 20, 2024. The proposal should include a study overview, sample cohort description, and scientific impact of the research. Proposals will be evaluated based on study design, hypothesis robustness, and scientific value.
The Inoviv selection committee—comprised of five PhD-level proteomics experts—will review and score each application. Additional information or interviews may be requested from shortlisted candidates.
- Applications are invited from scientists working in academic/research institutions or pharmaceutical companies.
- The proposal should involve the analysis of plasma samples, though other matrices may be considered for studies of exceptional scientific value.
- Samples must be shipped to Inoviv (UK) by March 7, 2025, at the awardee’s expense.
- The awardee will have permission to use and publish the data generated.
- Inoviv shall, in consultation with awardee, be able to utilize results in promotional materials.
- Applicants must agree to Inoviv’s MSA and the NeuroKey™ Grant Program’s terms.
- The grant winner will be publicly announced following the review process.
Key Benefits of NeuroKey™:
Targeted Biomarker Detection
Measure key neurodegenerative disease biomarkers, including Neurogranin (NRGN), Interleukin-18 (IL-18), and Brain-Derived Neurotrophic Factor (BDNF).
Multiplexed Assay
High-throughput analysis with Inoviv’s validated, mass spectrometry-based assay.
High Sensitivity
Detect low-abundance biomarkers with precision and reproducibility.
Scientific Support
Inoviv’s experts will provide data analysis, interpretation, and study design support to enhance your research outcomes.
Access the Application Form
Have Any Questions?
NeuroKey™ Grant Program
If you have any questions about the NeuroKey Grant Program, please submit a contact form and our proteomics experts will reach out
